Simplification / Commercialisation Clause Samples

The Simplification / Commercialisation clause is designed to streamline and clarify the terms of an agreement to ensure they are easily understood and commercially practical. In practice, this clause may require that contractual language be concise, avoid unnecessary legal jargon, and focus on the essential commercial terms relevant to the parties' business relationship. Its core function is to reduce ambiguity and complexity, making the contract more accessible and efficient for all parties involved, thereby minimizing misunderstandings and facilitating smoother business operations.
Simplification / Commercialisation. “In partnership with enterprise agencies and Interface…demonstrably simplified business access to the knowledge and expertise in Scottish universities”.
View SourceView Similar (4)
Simplification / Commercialisation. The University, in partnership with the Enterprise Agencies, Interface, and the Scottish HEI Sector strives to simplify business access to the knowledge and expertise in Scottish universities. Dundee participates in the UIF Enterprise Support Group (now a sub-group of US RCDG) and in the RCDG Contracts Sub-Group, both of which directly address this outcome. Dundee is recognised as a UK-leading university for commercialisation via commercial licensing and spin-out company formation. In 2021 it placed 6th in the UK in the University Spinout Report 2021 (Gorant), developing 1.5% of the UK’s spinouts with these companies raising £325.7 million over the past two decades, while in 2022 Dundee placed 4th in Beauhurst & Parkwalk “Equity Investment into UK Spin-outs”. These awards recognise outstanding success from companies such as Exscientia Ltd and Amphista Therapeutics Ltd , but also explicitly reference our entrepreneurial ecosystem (see also Outcome 4) We have made great strides over recent years in attracting investment from the global pharmaceutical industry – in 2020/21 our industry research income (HESA) rose to c. £15m. (around 20% of our total research income). We have also been able to invest commercially in Tay Therapeutics Ltd, one of our most high potential spin-outs, demonstrating the University’s commitment to this activity and to economic growth in our region. These successes depend on our continued commitment to deploying UIF in support of the ongoing activities of RIS, our Centre for Entrepreneurship (CfE) and School-based translational units such as the Drug Discovery Unit. We use the RCDG Contract Templates in all our dealings with Scottish-based industry partners and we have been progressively moving towards devolved standardised simple agreements (Non-Disclosure, Material Transfer, etc.) that can be signed off at School level thereby reducing transaction times for company partners. UIF will support our plans for 2022/23 and beyond in this area, including:
View SourceView Similar (2)
Simplification / Commercialisation. To simplify business access to the knowledge and expertise in Scottish universities.
View Source
Simplification / Commercialisation. In 2016 UWS developed three strategic themes around which it will focus teaching, research and enterprise activity: Sustainability, Health and Society. These themes have been a catalyst for cross disciplinary collaboration which is driving greater engagement with many of the Innovation Centres, Interface and with the Scottish Government’s proposed innovation reforms. UWS has had a particular focus on knowledge exchange in 2015/16, represented in part by our enhanced participation in schemes such as Knowledge Transfer Partnerships and Innovation Vouchers. From 15 to 16 UWS rose 20 places in the UK ranking table to be #3 in Scotland for KTP. In addition UWS accounted for 15% of the overall innovation voucher schemes run in Scotland which was 5% up on the previous year and ranked us among the top HEIs for the year. UWS sits on the Innovation Scotland Action Plan Implementation Group and is helping to lead the delivery of the important outcomes associated with this plan including a 16% increase in Start Ups in year One, the templating of contract types across all HEIs and the development of sector HEI liaison. • Target: We plan to continue this exceptional level of engagement and to maintain this grow level of 5% per annum. • Target: UWS is working towards a target of 15 start ups and spin outs by 2020
View Source
Simplification / Commercialisation. ‌ The plan for 2023/24 involves increasing core support for commercialisation. Targeting programs like iCure and the High Growth Spinout Programme will create a large opportunity pipeline. Over 2022/23, we have seen a notable improvement in our track record, demonstrating the effectiveness of our existing efforts. Building on this momentum, commercialisation opportunities will receive enhanced support from a scaled-up team including a group of high-profile EiRs and professional advisors. Increased resource from the UIF uplift will result in greater market engagement, enhancing commercialisation opportunities and strengthening industry partnerrships. Simplified university processes, bolstered resources and strong project management will ensure opportunities are optimally developed to align with the needs of the early-stage entrepreneurs and new ventures. Through these targeted efforts, a more supportive environment for commercialisation will be realised, ultimately contributing to the growth and success of high-potential ventures. Through consultations with Tech Scaler, Scotland's Chief Entrepreneur, SFC, and enterprise agencies, we will offer guidance on the 'Framework for Change,' aiming to incentivise universities to deliver quality commercialisation outcomes. The Business & Enterprise consistently strive to align program goals with economic development metrics used by Scottish Enterprise, Highlands and Islands Enterprise, and South of Scotland Enterprise.
View Source

Related to Simplification / Commercialisation

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Joint Commercialization Committee Upon a decision by the JSC to activate the joint Commercialization committee, but in no case later than eighteen (18) months prior to the projected First Commercial Sale (the “Joint Commercialization Committee” or “JCC”), the Parties shall establish the JCC. The JCC shall hold its initial meeting within thirty (30) days of its establishment. Following its initial meeting, the JCC will meet in person, by teleconference or by video-teleconference at least [***] per [***] to review and discuss material decisions and key activities that relate to the matters set forth below. The JCC will be responsible for the communication, review and discussion of the Commercialization Plan and other Commercialization matters, including marketing strategy and planning, pricing, commercial manufacture, and [***], in each case in the Territory. Without limiting the foregoing, the JCC shall be responsible for: (a) reviewing and consulting with Coherus on the Commercialization Plan prior to adoption of the Commercialization Plan or changes by Licensee; (b) recommending the Commercialization Plan for approval by the JSC prior to adoption of the Commercialization Plan; (c) communicating with the JDC regarding the interrelationship between Development activities and potential Commercialization activities; (d) reviewing and monitoring the activities and progress against the Commercialization Plan; (e) monitoring and reporting on the competitive landscape for the Product in the Territory; (f) establishing appropriate processes for coordinating review of promotional materials for the Territory to ensure compliance with Applicable Laws and industry best practices; (g) overseeing the trademark and publication strategies for the Territory; and (h) communicating with the Parties regarding all of the foregoing.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;